Dow Jones
39.869,38 -38,62 (-0,10%) Nasdaq
16.698,32 -44,07 (-0,26%) Nikkei 225
38.729,79 -190,47 (-0,49%) EUR/USD
1,0860 -0,0009 (-0,09%) Bitcoin EUR
60.353,93 -295,41 (-0,49%) CMC Crypto 200
1.377,75 -16,29 (-1,17%)
Roivant Sciences Ltd. (ROIV)
Dopo ore:
| Chiusura precedente | 11,50 |
| Aperto | 11,48 |
| Denaro | 11,40 x 1100 |
| Lettera | 11,43 x 1100 |
| Min-Max giorno | 11,34 - 11,48 |
| Intervallo di 52 settimane | 8,24 - 13,24 |
| Volume | |
| Media Volume | 6.672.141 |
| Capitalizzazione | 9,267B |
| Beta (5 anni mensile) | 1,30 |
| Rapporto PE (ttm) | 2,17 |
| EPS (ttm) | 5,27 |
| Prossima data utili | 26 giu 2024 - 01 lug 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 15,90 |
GlobeNewswireCovant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer
Vincent Hennemand Vincent Hennemand, CEO of Covant BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Covant Therapeutics, an innovative covalent drug discovery company, is pleased to announce the appointment of Vincent Hennemand as Chief Executive Officer (CEO). Vincent Hennemand is a seasoned executive with a distinguished career in the pharmaceutical and biotechnology industry. With an exceptional track record of leadership, a passion for advancing healthcare, novel classes of therapeutics, and in-dep
GlobeNewswireRoivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimabNo decrease in serum albumin below baseline or increase in low-density lipoprotein cholesterol (LDL-C) above baseline was observed after 4 weeks of dosing in the 300 mg multiple-ascending dose (MAD) SC cohortIMVT-1402 is being developed as a simple SC injection NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage
- GlobeNewswire
Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants
BASEL, Switzerland and LONDON and NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced the “Redemption Fair Market Value” to be used in connection with the previously announced redemption of its outstanding public warrants (the “Public Warrants”) and private placement warrants (the “Private Placement Warrants” and, together with the Public Warrants, the “Warrants”). The Redemption Fair Market Value will be used to determine the number of Roivant common shares (the “
